北大医药2024年净利润1.38亿元 费用成本全面优化

Core Insights - In 2024, the company reported a revenue of 2.06 billion yuan, a decrease of 6.10% year-on-year, while the net profit attributable to shareholders increased significantly by 211.10% to 138 million yuan [2][3] - The company achieved a non-recurring net profit of 127 million yuan, reflecting a growth of 221.05% compared to the previous year [2][3] - The basic earnings per share reached 0.23 yuan, with a return on equity of 9.32% [2][3] Financial Performance - Total revenue for 2024 was 2,060 million yuan, down from 2,194 million yuan in 2023, marking a decline of 6.10% [3] - The net profit attributable to shareholders rose to 138 million yuan from 44 million yuan in 2023, an increase of 211.10% [3] - The adjusted non-recurring net profit was 127 million yuan, up from 40 million yuan, representing a growth of 221.05% [3] - Operating cash flow net amount was 347 million yuan, a significant increase of 185.41% year-on-year [3][4] Cost Management - Total expenses were reduced to 338 million yuan, down by 267 million yuan year-on-year, with an expense ratio of 16.42% [2][4] - Sales expenses decreased by 56.03% due to channel optimization and market strategy adjustments [2][4] - Financial expenses dropped by 182.68% due to debt optimization [2][4] Business Segments - Revenue from the pharmaceutical manufacturing segment was 623 million yuan, a decline of 18.86% [4] - The pharmaceutical distribution segment saw a slight increase in revenue to 1.44 billion yuan, up by 0.78% [4] - Key products in the pharmaceutical industry, such as anti-infective and analgesic drugs, contributed to improved gross margins [4] Research and Development - R&D investment for 2024 was 40 million yuan, with a stable investment ratio of 1.95% [2][4] - The company received approval for one new raw material drug and completed submissions for three raw materials and formulations [4] - The company strengthened its portfolio in the allergy and chronic disease sectors by introducing eight new products [4]